Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk's stock rises as Ozempic beat analysts' expectations in sales
In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...